Pharsight

Drugs that contain Lisdexamfetamine Dimesylate

1. Vyvanse patents expiration

VYVANSE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(1 year, 1 month ago)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Feb, 2023

(1 year, 1 month ago)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(1 year, 1 month ago)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 1 month ago)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Aug, 2023

(7 months ago)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(7 months ago)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(7 months ago)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-703) Jan 30, 2018
New Chemical Entity Exclusivity(NCE) Feb 23, 2012
New Indication(I-645) Jan 31, 2015
M(M-188) Oct 14, 2019
New Patient Population(NPP) Nov 10, 2013
M(M-82) Apr 05, 2013

NCE-1 date: 23 February, 2011

Market Authorisation Date: 30 October, 2014

Treatment: Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disor...

Dosage: CAPSULE;ORAL

How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage

VYVANSE family patents

Family Patents